Literature DB >> 30861298

Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.

Neil Mehta1, Jennifer L Dodge2, Ryutaro Hirose2, John P Roberts2, Francis Y Yao1,2.   

Abstract

All patients with hepatocellular carcinoma meeting United Network for Organ Sharing T2 criteria currently receive the same listing priority for liver transplant (LT). A previous study from our center identified a subgroup with a very low risk of waitlist dropout who may not derive immediate LT benefit. To evaluate this issue at a national level, we analyzed within the United Network for Organ Sharing database 2052 patients with T2 hepatocellular carcinoma receiving priority listing from 2011 to 2014 in long wait time regions 1, 5, and 9. Probabilities of waitlist dropout were 18.3% at 1 year and 27% at 2 years. In multivariate analysis, factors associated with a lower risk of waitlist dropout included Model for End-Stage Liver Disease-Na < 15, Child's class A, single 2- to 3-cm lesion, and α-fetoprotein ≤20 ng/mL. The subgroup of 245 (11.9%) patients meeting these 4 criteria at LT listing had a 1-year probability of dropout of 5.5% vs 20% for all others (P < .001). On explant, the low dropout risk group was more likely to have complete tumor necrosis (35.5% vs 24.9%, P = .01) and less likely to exceed Milan criteria (9.9% vs 17.7%, P = .03). We identified a subgroup with a low risk of waitlist dropout who should not receive the same LT listing priority.
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Organ Procurement and Transplantation Network (OPTN); United Network for Organ Sharing (UNOS); clinical research/practice; health services and outcomes research; liver disease malignant; liver transplantation/hepatology; organ allocation; organ procurement and allocation; recipient selection

Mesh:

Year:  2019        PMID: 30861298      PMCID: PMC7072024          DOI: 10.1111/ajt.15353

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  37 in total

1.  Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.

Authors:  Alessandro Cucchetti; Matteo Cescon; Eleonora Bigonzi; Fabio Piscaglia; Rita Golfieri; Giorgio Ercolani; Maria Cristina Morelli; Matteo Ravaioli; Antonio Daniele Pinna
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

2.  Waiting list removal rates among patients with chronic and malignant liver diseases.

Authors:  R B Freeman; E B Edwards; A M Harper
Journal:  Am J Transplant       Date:  2006-06       Impact factor: 8.086

3.  Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.

Authors:  Neil Mehta; Monika Sarkar; Jennifer L Dodge; Nicholas Fidelman; John P Roberts; Francis Y Yao
Journal:  Liver Transpl       Date:  2016-01-08       Impact factor: 5.799

4.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

5.  Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list.

Authors:  Mariya L Samoylova; Mark J Nigrini; Jennifer L Dodge; John P Roberts
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

Review 6.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

7.  Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.

Authors:  Vatche G Agopian; Maud M Morshedi; Justin McWilliams; Michael P Harlander-Locke; Daniela Markovic; Ali Zarrinpar; Fady M Kaldas; Douglas G Farmer; Hasan Yersiz; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

8.  Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.

Authors:  Sarah K Alver; Douglas J Lorenz; Michael R Marvin; Guy N Brock
Journal:  Liver Transpl       Date:  2016-10       Impact factor: 5.799

9.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

10.  Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.

Authors:  Neil Mehta; Julie Heimbach; Denise M Harnois; Gonzalo Sapisochin; Jennifer L Dodge; David Lee; Justin M Burns; William Sanchez; Paul D Greig; David R Grant; John P Roberts; Francis Y Yao
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

View more
  7 in total

1.  The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.

Authors:  Sarah Bernards; Ryutaro Hirose; Francis Y Yao; Chengshi Jin; Jennifer L Dodge; Chiung-Yu Huang; Neil Mehta
Journal:  Liver Transpl       Date:  2021-12-08       Impact factor: 5.799

2.  A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Francis Y Yao
Journal:  J Hepatol       Date:  2020-11-11       Impact factor: 25.083

Review 3.  Artificial Intelligence in hepatology, liver surgery and transplantation: Emerging applications and frontiers of research.

Authors:  Fadl H Veerankutty; Govind Jayan; Manish Kumar Yadav; Krishnan Sarojam Manoj; Abhishek Yadav; Sindhu Radha Sadasivan Nair; T U Shabeerali; Varghese Yeldho; Madhu Sasidharan; Shiraz Ahmad Rather
Journal:  World J Hepatol       Date:  2021-12-27

4.  Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.

Authors:  Nicole E Rich; Binu V John; Neehar D Parikh; Ian Rowe; Neil Mehta; Gaurav Khatri; Smitha M Thomas; Munazza Anis; Mishal Mendiratta-Lala; Christopher Hernandez; Mobolaji Odewole; Latha T Sundaram; Venkata R Konjeti; Shishir Shetty; Tahir Shah; Hao Zhu; Adam C Yopp; Yujin Hoshida; Francis Y Yao; Jorge A Marrero; Amit G Singal
Journal:  Hepatology       Date:  2020-10-25       Impact factor: 17.425

Review 5.  Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.

Authors:  Neil Mehta; Neehar Parikh; R Katie Kelley; Bilal Hameed; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2020-07-08       Impact factor: 11.382

Review 6.  Hepatocellular Carcinoma-How to Determine Therapeutic Options.

Authors:  Neil Mehta
Journal:  Hepatol Commun       Date:  2020-01-22

7.  Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.

Authors:  Jordyn Silverstein; Garrett Roll; Jennifer L Dodge; Joshua D Grab; Francis Y Yao; Neil Mehta
Journal:  Liver Transpl       Date:  2020-07-21       Impact factor: 5.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.